Clinical study to evaluate the efficacy and safety of a unani formulation in Kalaf (Melasma).
Phase 2
- Conditions
- Health Condition 1: L811- Chloasma
- Registration Number
- CTRI/2023/03/050201
- Lead Sponsor
- ational Research Institute of Unani Medicine for Skin Disorders.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Participant having single or multiple, irregular or regular, light to dark brown macules on the face (cheeks, nose, forehead, upper lip and chin).
Chronicity of disease should be more than 4 months.
Exclusion Criteria
women who are pregnant and lactating.
Participant aged less than 18 years and more than 55 years.
Significant cardiovascular / pulmonary / hepato-renal dysfunction.
Known case of diabetes mellitus, HIV / AIDS and malignancy.
Those unwilling to come for regular follow-up for the entire duration of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 27% reduction in MASI score from baseline after 8 weeks of treatment.Timepoint: 8 weeks
- Secondary Outcome Measures
Name Time Method Systemic safety assessmentTimepoint: 8 weeks